Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 10Dermatologic 5Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 191pembrolizumab 155Pemetrexed 134Cisplatin 117durvalumab 71Paclitaxel 71osimertinib 67Nivolumab 66Docetaxel 63Specimen Handling 61atezolizumab 57Magnetic Resonance Spectroscopy 50Etoposide 46Gemcitabine 42Radiotherapy 39Radiosurgery 37130-nm albumin-bound paclitaxel 34Drug Therapy 30Cetuximab 28Bevacizumab 27Ipilimumab 25Taxes 23cemiplimab 22tislelizumab 20Platinum 20amivantamab 18Radiation 18Immunoglobulin G 171,2-diaminocyclohexaneplatinum II citrate 17Disulfides 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dacarbazine × Thoracic × 90 days × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡